Brokerages predict that PerkinElmer, Inc. (NYSE:PKI) will post sales of $615.80 million for the current quarter, according to Zacks. Six analysts have made estimates for PerkinElmer’s earnings, with estimates ranging from $613.15 million to $619.70 million. PerkinElmer posted sales of $566.77 million during the same quarter last year, which would indicate a positive year over year growth rate of 8.7%. The company is expected to report its next earnings report after the market closes on Thursday, January 25th.
On average, analysts expect that PerkinElmer will report full year sales of $615.80 million for the current financial year, with estimates ranging from $2.23 billion to $2.24 billion. For the next financial year, analysts expect that the business will report sales of $2.42 billion per share, with estimates ranging from $2.33 billion to $2.70 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that cover PerkinElmer.
PerkinElmer (NYSE:PKI) last posted its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.73 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.72 by $0.01. The business had revenue of $554.28 million during the quarter, compared to analyst estimates of $552.38 million. PerkinElmer had a net margin of 18.27% and a return on equity of 13.11%.
In other news, Director Nicholas A. Lopardo sold 24,050 shares of the company’s stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $70.72, for a total value of $1,700,816.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Alexis P. Michas sold 5,000 shares of the company’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $73.18, for a total transaction of $365,900.00. The disclosure for this sale can be found here. In the last three months, insiders sold 86,336 shares of company stock worth $6,114,917. Insiders own 2.20% of the company’s stock.
Institutional investors have recently modified their holdings of the business. Cutler Group LP grew its holdings in PerkinElmer by 845.7% during the 4th quarter. Cutler Group LP now owns 2,237 shares of the medical research company’s stock worth $163,000 after acquiring an additional 2,537 shares in the last quarter. Waldron LP bought a new stake in shares of PerkinElmer in the 3rd quarter valued at about $200,000. Seaward Management Limited Partnership bought a new stake in shares of PerkinElmer in the 3rd quarter valued at about $202,000. Carret Asset Management LLC bought a new stake in shares of PerkinElmer in the 2nd quarter valued at about $210,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of PerkinElmer in the 2nd quarter valued at about $269,000. Institutional investors own 91.39% of the company’s stock.
PerkinElmer (NYSE:PKI) opened at $81.20 on Tuesday. The firm has a market cap of $8,940.00, a P/E ratio of 36.74, a price-to-earnings-growth ratio of 1.92 and a beta of 0.77. PerkinElmer has a 12-month low of $50.59 and a 12-month high of $81.30. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.59 and a quick ratio of 2.09.
The company also recently announced a quarterly dividend, which will be paid on Friday, February 9th. Stockholders of record on Friday, January 19th will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.34%. The ex-dividend date of this dividend is Thursday, January 18th. PerkinElmer’s dividend payout ratio is currently 12.67%.
TRADEMARK VIOLATION WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/23/zacks-brokerages-expect-perkinelmer-inc-pki-will-announce-quarterly-sales-of-615-80-million.html.
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.